Nov 21, 2023 / 01:00PM GMT
Presentation
Nov 21, 2023 / 01:00PM GMT
=====================
Corporate Participants
=====================
* Christian Rommel
Bayer Aktiengesellschaft - Head of Research & Development at Pharmaceuticals Division
* Jost Reinhard
Bayer Aktiengesellschaft - Head of IR
* Stefan Oelrich
Bayer Aktiengesellschaft - Head of the Pharmaceuticals Division & Member of the Board of Management
* William N. Anderson
Bayer Aktiengesellschaft - Chairman of the Management Board & CEO
* Wolfgang U. Nickl
Bayer Aktiengesellschaft - CFO & Member of Management Board
=====================
Conference Call Participants
=====================
* Alycia Samsudin
* Charles Bentley
Jefferies LLC, Research Division - Equity Analyst
* Damien Conover
Morningstar Inc., Research Division - Sector Director and Equities Strategist
* Gunther Zechmann
Sanford C. Bernstein & Co., LLC., Research Division - Research Analyst
* Peter Verdult
Citigroup Inc.,
Bayer AG
(MIL:1BAYN)
€
47
+7.32 (+18.45%)
Market Cap: 46.17 Bil
Enterprise Value: 74.89 Bil
PE Ratio: 0
PB Ratio: 1.33
GF Score: 58/100 Bayer AG to Share the Background and First Assessments of OCEANIC-AF Trial Presentation Transcript
Nov 21, 2023 / 01:00PM GMT
Release Date Price:
€34.48
(+0.80%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot